Timothy COWAN, Nada ABU ALRUB, Anna WİLSON, Mani MAKHİJA, Dedee MURRELL

Eksfolyatif keilit tedavisinde tildrakizumab

Anahtar Kelimeler:

biyolojik, keilit, tildrakizumab, interlökin-23, dermatoloji

Tildrakizumab for the treatment of exfoliative cheilitis

Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.

Keywords:

tildrakizumab, interleukin-23, biologic, cheilitis, dermatology,

PDF

___

Cai L, Wei J, Ma D, et al. Predisposition of hypersensitivity in patients with exfoliative cheilitis. J Dent Sci 2022;17:476-81.
Georgakopoulou E, Loumou P, Grigoraki A, Panagiotopoulos A. Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%. Med Oral Patol Oral Cir Bucal 2021;26:e357-e60.
Liu J, Shi L, Wang X, et al. Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration. J Oral Pathol Med 2021;50:251-9.
Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005;141:1080-2.
Gueutier A, Leducq S, Joly A, Picon L, Vaillant L, Samimi M. Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors. Int J Dermatol 2019;58:e236-e7.
Taxonera C, Alba C, Colmenares M, Olivares D, Rey E. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review. Therap Adv Gastroenterol 2020;27:13.

ISSN: 2651-2750
Yayın Aralığı: Yılda 3 Sayı
Başlangıç: 2018
Yayıncı: Doğu Karadeniz Deri ve Zührevi Hastalıklar Derneği

Arşiv